2024年6月最新影响因子数据已经更新,欢迎查询! 如果您对期刊系统有任何需求或者问题,欢迎
反馈给我们。基本信息 | 登录收藏 | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
期刊名字 | Infectious Diseases and Therapy INFECT DIS THER (此期刊被最新的JCR期刊SCIE收录) LetPub评分 6.9
50人评分
我要评分
声誉 8.3 影响力 5.8 速度 7.0 | |||||||||||||||||||||
期刊ISSN | 2193-8229 | 微信扫码收藏此期刊 | ||||||||||||||||||||
E-ISSN | 2193-6382 | |||||||||||||||||||||
2023-2024最新影响因子 (数据来源于搜索引擎) | 4.7 点击查看影响因子趋势图 | |||||||||||||||||||||
实时影响因子 | 截止2024年10月29日:3.777 | |||||||||||||||||||||
2023-2024自引率 | 4.30%点击查看自引率趋势图 | |||||||||||||||||||||
五年影响因子 | 4.6 | |||||||||||||||||||||
JCI期刊引文指标 | 0.93 | |||||||||||||||||||||
h-index | 暂无h-index数据 | |||||||||||||||||||||
CiteScore ( 2024年最新版) |
| |||||||||||||||||||||
期刊简介 |
| |||||||||||||||||||||
期刊官方网站 | https://www.springer.com/40121 | |||||||||||||||||||||
期刊投稿网址 | https://www.editorialmanager.com/inth | |||||||||||||||||||||
作者指南网址 | https://www.springer.com/40121/submission-guidelines | |||||||||||||||||||||
期刊语言要求 | Language Presenting your work in a well-structured manuscript and in well-written English gives it its best chance for editors and reviewers to understand it and evaluate it fairly. Many researchers find that getting some independent support helps them present their results in the best possible light. 经LetPub语言功底雄厚的美籍native English speaker精心编辑的稿件,不仅能满足Infectious Diseases and Therapy的语言要求,还能让Infectious Diseases and Therapy编辑和审稿人得到更好的审稿体验,让稿件最大限度地被Infectious Diseases and Therapy编辑和审稿人充分理解和公正评估。LetPub的专业SCI论文编辑服务(包括SCI论文英语润色,同行资深专家修改润色,SCI论文专业翻译,SCI论文格式排版,专业学术制图等)帮助作者准备稿件,已助力全球15万+作者顺利发表论文。部分发表范例可查看:服务好评 论文致谢 。 提交文稿 | |||||||||||||||||||||
是否OA开放访问 | Yes | |||||||||||||||||||||
OA期刊相关信息 | 文章处理费:需要( GBP4700; USD6850; EUR5500; ) 文章处理费豁免:查看说明 其他费用:没有 期刊主题关键词:pharmacoeconomics、public health、infectious diseases、epidemiology 相关链接:Aims & ScopeAuthor InstructionsEditorial BoardAnonymous peer review | |||||||||||||||||||||
通讯方式 | 236 GRAYS INN RD, 6TH FLOOR, LONDON, ENGLAND, WC1X 8HL | |||||||||||||||||||||
出版商 | Springer Healthcare | |||||||||||||||||||||
涉及的研究方向 | Medicine-Microbiology (medical) | |||||||||||||||||||||
出版国家或地区 | ENGLAND | |||||||||||||||||||||
出版语言 | English | |||||||||||||||||||||
出版周期 | 6 issues per year | |||||||||||||||||||||
出版年份 | 2012 | |||||||||||||||||||||
年文章数 | 144点击查看年文章数趋势图 | |||||||||||||||||||||
Gold OA文章占比 | 98.50% | |||||||||||||||||||||
研究类文章占比: 文章 ÷(文章 + 综述) | 77.78% | |||||||||||||||||||||
WOS期刊SCI分区 ( 2023-2024年最新版) | WOS分区等级:1区
| |||||||||||||||||||||
中国科学院《国际期刊预警 名单(试行)》名单 | 2024年02月发布的2024版:不在预警名单中 2023年01月发布的2023版:不在预警名单中 2021年12月发布的2021版:不在预警名单中 2020年12月发布的2020版:不在预警名单中 | |||||||||||||||||||||
中国科学院SCI期刊分区 ( 2023年12月最新升级版) | 点击查看中国科学院SCI期刊分区趋势图
| |||||||||||||||||||||
中国科学院SCI期刊分区 ( 2022年12月升级版) |
| |||||||||||||||||||||
中国科学院SCI期刊分区 ( 2021年12月旧的升级版) |
| |||||||||||||||||||||
SCI期刊收录coverage | Science Citation Index Expanded (SCIE) (2020年1月,原SCI撤销合并入SCIE,统称SCIE) Scopus (CiteScore) Directory of Open Access Journals (DOAJ) | |||||||||||||||||||||
PubMed Central (PMC)链接 | http://www.ncbi.nlm.nih.gov/nlmcatalog?term=2193-8229%5BISSN%5D | |||||||||||||||||||||
平均审稿速度 | 网友分享经验: 6 Weeks | |||||||||||||||||||||
平均录用比例 | 网友分享经验: | |||||||||||||||||||||
版面费/APC文章处理费信息 | 文章处理费:需要( GBP4700; USD6850; EUR5500; ) 文章处理费豁免:查看说明 其他费用:没有 LetPub提供文章处理费(APC)支持服务,可以用人民币支付版面费啦! | |||||||||||||||||||||
LetPub助力发表 | 经LetPub编辑的稿件平均录用比例是未经润色的稿件的1.5倍,平均审稿时间缩短40%。众多作者在使用LetPub的专业SCI论文编辑服务(包括SCI论文英语润色,同行资深专家修改润色,SCI论文专业翻译,SCI论文格式排版,专业学术制图等)后论文在Infectious Diseases and Therapy顺利发表。
快看看作者怎么说吧:服务好评 论文致谢 | |||||||||||||||||||||
期刊常用信息链接 |
|
|
|
中国学者近期发表的论文 | |
1. | Non-invasive Assessment of Liver Fibrosis Regression in Patients with Chronic Hepatitis B: A Retrospective Cohort Study Author: Xu, Wei; Hu, Qiankun; Chen, Chong; Li, Weixia; Li, Qiang; Chen, Liang Journal: INFECTIOUS DISEASES AND THERAPY. 2023; Vol. 12, Issue 2, pp. 487-498. DOI: 10.1007/s40121-022-00738-1 PubMed DOI |
2. | Retrospective Analysis of Epidemiology, Risk Factors, and Outcomes of Health Care-Acquired Carbapenem-Resistant Klebsiella pneumoniae Bacteremia in a Chinese Tertiary Hospital, 2010-2019 Author: Li, Meng; Yang, Shanshan; Yao, Hongwu; Liu, Yunxi; Du, Mingmei Journal: INFECTIOUS DISEASES AND THERAPY. 2023; Vol. 12, Issue 2, pp. 473-485. DOI: 10.1007/s40121-022-00732-7 PubMed DOI |
3. | Association Between Lactate and 28-Day Mortality in Elderly Patients with Sepsis: Results from MIMIC-IV Database Author: He, Liudang; Yang, Donghua; Ding, Qiong; Su, Yingjie; Ding, Ning Journal: INFECTIOUS DISEASES AND THERAPY. 2023; Vol. 12, Issue 2, pp. 459-472. DOI: 10.1007/s40121-022-00736-3 PubMed DOI |
4. | Comparison of the Distribution and Changes in the Antibiotic Resistance of Clinical Bacterial Isolates from the Lower Respiratory Tract of Children in Shenzhen Before the Epidemic, During the Epidemic, and During the Period of Normalized Prevention and Control of COVID-19 Author: Meng, Qing; Li, Wujiao; Jiang, Hanfang; Yan, Huimin; Wang, Heping; Ye, Binjun; Zhou, Lintao; Chen, Yunsheng Journal: INFECTIOUS DISEASES AND THERAPY. 2023; Vol. 12, Issue 2, pp. 563-575. DOI: 10.1007/s40121-022-00751-4 PubMed DOI |
5. | The Association Between Alveolar-Arterial Oxygen Tension Difference and the Severity of COVID-19 in Patients Author: Xie, Canbin; Deng, Jiayi; Li, Fanglin; Wu, Chenfang; Xu, Min; Yu, Bo; Wu, Guobao; Zhong, Yanjun; Tang, Da; Li, Jinxiu Journal: INFECTIOUS DISEASES AND THERAPY. 2023; Vol. 12, Issue 2, pp. 577-587. DOI: 10.1007/s40121-022-00752-3 PubMed DOI |
6. | Effective Analysis of Antiviral Treatment in Patients with HBeAg-Seropositive Chronic Hepatitis B with ALT < 2 Upper Limits of Normal: A Multi-center Retrospective Cohort Study Author: Hu, Meixin; Liao, Guichan; Wei, Sufang; Qian, Zhe; Chen, Hongjie; Xia, Muye; Xie, Qiuli; Peng, Jie Journal: INFECTIOUS DISEASES AND THERAPY. 2023; Vol. 12, Issue 2, pp. 637-647. DOI: 10.1007/s40121-022-00757-y PubMed DOI |
7. | Safety and Efficacy of Paxlovid Against Omicron Variants of Coronavirus Disease 2019 in Elderly Patients Author: Weng, Chengzhao; Xie, Rongcheng; Han, Guanjie; Yuan, Ya; Li, Shiqin; Wang, Chao; Wang, Xiaofeng; Jiang, Wei; Jiang, Libo Journal: INFECTIOUS DISEASES AND THERAPY. 2023; Vol. 12, Issue 2, pp. 649-662. DOI: 10.1007/s40121-023-00760-x PubMed DOI |
8. | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Anti-C5a Antibody BDB-001 for Severe COVID-19: A Randomized, Double-Blind, Placebo-Controlled Phase 1 Clinical Trial in Healthy Chinese Adults Author: Chen, Guiling; Li, Nan; Dai, Xiahong; Tu, Shiyan; Shen, Zhenwei; Wu, Kaiqi; Jin, Tinghan; Wu, Jiajun; Peng, Conggao; Sheng, Guoping; Zhu, Mengfei; Tang, Lingling; Li, Lanjuan Journal: INFECTIOUS DISEASES AND THERAPY. 2023; Vol. 12, Issue 2, pp. 663-675. DOI: 10.1007/s40121-023-00759-4 PubMed DOI |
9. | Effect of Anti-HBs on Mortality Among Resolved HBV Infection: a Population-Based Prospective Cohort Study Author: Huang, Shuai-Wen; Li, Xi-Tang; Chen, Chen; Ning, Qin; Huang, Jia-Quan Journal: INFECTIOUS DISEASES AND THERAPY. 2023; Vol. 12, Issue 3, pp. 871-890. DOI: 10.1007/s40121-023-00766-5 PubMed DOI |
10. | Risk Factors for Melioidosis Mortality and Epidemics: A Multicentre, 10-Year Retrospective Cohort Study in Northern Hainan Author: Zheng, Wanting; Kuang, Shicheng; Zhong, Chengwang; Zhou, Jing; Long, Wenfang; Xiao, Sha; Wu, Biao Journal: INFECTIOUS DISEASES AND THERAPY. 2023; Vol. 12, Issue 3, pp. 951-964. DOI: 10.1007/s40121-023-00768-3 PubMed DOI |
|
|
|
联系我们 | 站点地图 | 友情链接 | 授权代理商 | 加入我们
© 2010-2024 中国: LetPub上海 网站备案号:沪ICP备10217908号-1 沪公网安备号:31010402006960 (网站)31010405000484 (蝌蝌APP)
增值电信业务经营许可证:沪B2-20211595 网络文化经营许可证:沪网文[2023]2004-152号
礼翰商务信息咨询(上海)有限公司 办公地址:上海市徐汇区漕溪北路88号圣爱大厦1803室